Mesoporous lipid-silica nanohybrids for folate-targeted drug-resistant ovarian cancer
New J. Chem., 2018, Accepted Manuscript DOI: 10.1039/C7NJ03334F, PaperSayan Samanta, Lina Pradhan, Dhirendra Bahadur Folic acid (FA) targets cancer by exploiting its overexpression of folic acid receptors (FR). A novel folate conjugated lipid coated mesoporous silica nanoparticle has been synthesized in this study to... The content of this RSS Feed (c) The Royal Society of Chemistry
According to the study from the U.S. National Cancer Institute, these trends were also observed for endometrial cancer as well.
Condition: Non-Germline BRCA Mutated Ovarian Cancer Intervention: Drug: Olaparib Sponsors: AstraZeneca; Quintiles, Inc.; Myriad Genetics, Inc.; Covance; Theradex; Parexel Not yet recruiting
(Oxford University Press USA) A study published in the Journal of the National Cancer Institute indicates that screening the general population for mutations in specific genes is a more cost effective way to detect people at risk and prevents more breast and ovarian cancers compared to only screening patients with a personal or family history of these diseases.
ALL BRITISH women over the age of 30 should be tested for breast and ovarian cancer gene mutations to help save lives and cut costs, new research suggests.
A single administration of hyperthermic intraperitoneal chemotherapy at the end of cytoreductive surgery improves overall survival in women with advanced ovarian cancer.Medscape Medical News
(Reuters Health) - - A heated chemotherapy organ bath circulated throughout the abdomen after surgery can significantly prolong a woman's survival with advanced ovarian cancer, according to doctors testing the new treatment.
BRCA1 methylation in normal tissue raises the risk for high-grade ovarian cancer and may occur before birth, according to a study from Norway.Reuters Health Information
Condition: Cancer - Ovarian Interventions: Drug: Veliparib, capsule; Drug: Veliparib, tablet; Drug: Carboplatin; Drug: Paclitaxel Sponsor: AbbVie Not yet recruiting
Mesonephric adenocarcinoma most commonly arises in the cervix and is presumed to be derived from normal or hyperplastic mesonephric remnants. It is characterized by recurrent KRAS mutations and lack of PIK3CA/PTEN alterations. Adenocarcinomas of the uterine corpus and ovary characterized by morphologic and immunophenotypic similarities to mesonephric adenocarcinoma have been reported. The pathogenesis of these tumors, which have been designated “mesonephric-like adenocarcinomas” is unknown, and it has been debated whether these represent mesonephric adenocarcinomas that arise in the endometrium/ovary or endomet...